Deal Watch: GSK Declines Option As Ionis' Inotersen Nears Finish Line
Executive Summary
Ionis will file polyneuropathy candidate in US and EU on its own, while GSK de-emphasizes rare diseases. Aclaris buys Confluence in earn-out-heavy deal, and Galena undertakes reverse merger with Sellas.
You may also be interested in...
GSK Opts In On Ionis’ Antisense Candidates For Hep B
The pharma is taking over a pair of Ionis candidates intended to address the underlying cause of HBV, possibly offering a curative therapy. It’s just the second HBV licensing agreement in 2019, after heavier deal flow in recent years.
Valneva/Emergent BioSolutions' Candidate Zika Vaccine Shows Early Clinical Promise
A European/US company collaboration has reported encouraging safety and immunogenicity in early clinical studies with an alum-adjuvanted Zika vaccine based on inactivated whole virus.
Ionis Catches The Eye With New Roche Alliance
October has been a very good month for Ionis. Following US approval of Tegredi, it has now signed a potentially lucrative deal with existing partner Roche for another antisense drug, this time to tackle advanced dry AMD.